

Βιβλιογραφία πηγή Β (Μετα-αναλύσεις, Συστηματικές Ανασκοπήσεις, Τυχοιοποιημένες Κλινικές Δοκιμές, κ.α.)

Reference source B (Meta-analysis, Systematic Reviews, Randomized Controlled Trials, e.t.c.)

1. Mant J, Doust J, Roalfe A, Barton P, Cowie MR, Glasziou P, *et al.* Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. *Health Technol Assess* 2009; **13**(32).
2. Fonseca C, Sarmiento PM, Minez A, Goncalves E, Covas R, Dias AR, *et al.* Comparative value of BNP and NT-proBNP in diagnosis of heart failure. *Rev Port Cardiol* 2004; **23**: 979–91.
3. Alehagen U, Lindstedt G, Eriksson H, Dahlstrom U. Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care. *Clin Chem* 2003; **49**: 1337–46.
4. Hobbs FDR, Davis RC, Roalfe AK, Hare R, Davies MK. Reliability of N-terminal pro-BNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations. *Heart* 2004; **90** :866–70.
5. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, *et al.* Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. *Lancet* 1997; **350**: 1349–53.
6. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. *J Am Coll Cardiol* 2002; **39**: 202–9.
7. Galasko GI, Lahiri A, Barnes SC. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? *Eur Heart J* 2005; **26**: 2269–76.
8. Rutten FH, Moons KG, Cramer MJ, Grobbee DE, Zuithoff NP, Lammers JW, *et al.* Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. *BMJ* 2005; **331** :1379.
9. Fox KF, Cowie MR, Wood DA, Coats AJ, Poole-Wilson PA, Sutton GC. A rapid access heart failure clinic provides a prompt diagnosis and appropriate management of new heart failure presenting in the community. *Eur J Heart Fail* 2000;**2**:423–9.
10. Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, *et al.* Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heartfailure diagnosis in primary care: a randomized, controlled trial. *J Am Coll Cardiol* 2003;**42**:1793–800.
11. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T, *et al.* The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. *Eur J Heart Fail* 2005;**7**:537–41.
12. Jose JV, Gupta SN, Selvakumar D. Utility of N-terminal pro-brain natriuretic peptide for the diagnosis of heart failure. *Indian Heart J* 2003; **55**: 35–9.
13. Knudsen CW, Omland T, Clopton P, Westheim A, Abraham WT, Storrow AB, *et al.* Diagnostic value of B-type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. *Am J Med* 2004; **116**: 363–8.
14. Logeart D, Saudubray C, Beyne P, Thabut G, Ennezat PV, Chavelas C, *et al.* Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. *J Am Coll Cardiol* 2002; **40**: 1794–800.
15. Rutten FH, Moons KG, Cramer MJ, Grobbee DE, Zuithoff NP, Lammers JW, *et al.* Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. *BMJ* 2005; **331** :1379.

16. Mueller T, Gegenhuber A, Dieplinger B. Capability of B-type natriuretic peptide (BNP) and aminoterminal proBNP as indicators of cardiac structural disease in asymptomatic patients with systemic arterial hypertension. *Clin Chem* 2005; **51**:2245–51.
17. Lim TK, Senior R. Noninvasive modalities for the assessment of left ventricular function: all are equal but some are more equal than others. *J Nucl Cardiol* 2006; **13**: 445–9.
18. Cost B. *Heart failure in the elderly*. PhD thesis. University of Erasmus, Rotterdam; 2000.
19. Misuraca G, Serafini O, Caporale R, Battista F, Plastina F. Diagnosis of heart failure in general medicine: role of cerebral natriuretic peptide. Results of a pilot study of a population sample from Calabria. *Ital Heart J* 2002;**3** (Suppl. 9):928–32.
20. Ababsa R, Jourdain P, Funck F, Deschamps P, Sadeg N. BNP and dyspnea: proposition of a diagnostic strategy based on two cut-offs. *Ann Biol Clin (Paris)* 2005;**63** :213–16.
21. Alibay Y, Beauchet A, El Mahmoud R, Schmitt C, Brun-Ney, D, Benoit MO, *et al*. Plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea. *Biomed Pharmacother* 2005; **59**: 20–4.
22. Barcarse E, Kazanegra R, Chen A, Chiu A, Clopton P, Maisel A. Combination of B-type natriuretic peptide levels and non-invasive hemodynamic parameters in diagnosing congestive heart failure in the emergency department. *Congest Heart Fail* 2004; **10**:171–6.
23. El Mahmoud R, Alibay Y, Brun-Ney D, Boulard JC, Dubourg O, Puy H, *et al*. Type B natriuretic peptide (BNP) versus n-terminal type B natriuretic propeptide in the diagnosis of cardiac failure in the elderly over 75 population. *Arch Mal Coeur Vaiss* 2006; **99**: 201–7.
24. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. *J Am Coll Cardiol* 2003; **42**: 728– 35.
25. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, *et al*. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med* 2002; **347**: 161–7.
26. Villacorta H, Duarte A, Duarte NM, Carrano A, Mesquita ET, Dohmann HJ, *et al*. The role of B-type natriuretic peptide in the diagnosis of congestive heart failure in patients presenting to an emergency department with dyspnea. *Arq Bras Cardiol* 2002; **79**: 569–72, 564–8.
27. Jourdain P, Funck F, Canault E, Bellorini M, Deschamps P, Duval G, *et al*. Value of type B natriuretic peptide in the emergency management of patients with suspected cardiac failure. Report of 125 cases. *Arch Mal Coeur Vaiss* 2002; **95** :763–7.
28. Ray P, Arthaud M, Lefort Y, Birolleau S, Beigelman C, Riou B. Usefulness of B-type natriuretic peptide in elderly patients with acute dyspnea. *Intensive Care Med* 2004; **30**: 2230–6.
29. Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, *et al*. Plasma brain natriuretic peptide in assessment of acute dyspnoea. *Lancet* 1994; **343**: 440– 4.
30. Dokainish H, Zoghbi WA, Lakkis NM, Quinones MA, Nagueh SF. Comparative accuracy of B-type natriuretic peptide and tissue Doppler echocardiography in the diagnosis of congestive heart failure. *Am J Cardiol* 2004; **93**: 1130–5.
31. McLean AS, Tang B, Nalos M, Huang SJ, Stewart DE. Increased B-type natriuretic peptide (BNP) level is a strong predictor for cardiac dysfunction in intensive care unit patients. *Anaesth Intensive Care* 2003; **31** : 21–7.
32. Nielsen LS, Svanegaard J, Klitgaard NA, Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. *Eur J Heart Fail* 2004; **6**: 63–70.
33. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, Lopez L, Cotes C, Bellido J, *et al*. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. *Eur J Heart Fail* 2004; **6**: 301–8.
34. Januzzi JL, Jr, Camargo CA, Anwarudin S, Baggish AL, Chen AA, Krauser DG, *et al*. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. *Am J Cardiol* 2005; **95**: 948–54.
35. Berdague P, Caffin PY, Barazer I. Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients. *Am Heart J* 2006; **151**: 690–8.

36. Pfeffer MA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. *N Engl J Med* 1992;327:821–8.
37. Nicklas JM, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N Engl J Med* 1992;327:685–91.
38. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. *N Engl J Med* 1991;325: 293–302.
39. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *N Engl J Med* 1987;316:1429–35.
40. Pflugfelder PW, Baird MG, Tonkon MJ. Clinical consequences of angiotensin-converting-enzyme inhibitor withdrawal in chronic heart failure: a doubleblind placebo-controlled study of quinapril. *J Am Coll Cardiol* 1993;22: 1557–63.
41. Packer M, Bristow MR, Cohn JN. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. *N Engl J Med* 1996;334:1349–55.
42. Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet* 1999;353:2001–7.
43. CIBIS II investigators and committees. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomized trial. *Lancet* 1999;353 :9–13.
44. Packer M, Coates AJ, Fowler MB, for the Carvedilol Prospective Randomised Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the survival of patients with severe chronic heart failure. *New Engl J Med* 2001;344:1651–8.
47. Pitt B, Segal R, Martinez FA. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet* 1997;349:747–52.
48. Pitt B, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. *Lancet* 2000;355(9215):1582–7.
49. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. *Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan*. *Lancet* 2002;360(9335): 752–60.
50. Pfeffer MA, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003;349(20):1893–906.
51. McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. *Lancet* 2003;362(9386):767–71.
52. van Veldhuisen DJ, Man-in-'t-Veld-AJ, Dunselman PH, Lok DJ, Dohmen HJ, Poortermans JC *et al*. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). *Journal of the American College of Cardiology* 1993;**22**:1564–73.
53. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. *Journal of the American College of Cardiology* 1993;**22**:955–62.
54. McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs R *et al*. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. *European Journal of Heart Failure* 2001;**3**:495–502.
55. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. *New England Journal of Medicine* 1997;**336**:525–33.
56. Cowley AJ, Stainer K, Wynne RD, Rowley JM, Hampton JR. Symptomatic assessment of patients with heart failure: double-blind comparison of increasing doses of diuretics and captopril in moderate heart failure. *Lancet* 1986;**2**:770–2.

58. Pitt B, Zannad F, Remme WJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med* 1999;341:709–17.
59. Zannad F, McMurray JJ, Krum H, et al; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med* 2011;364(1):11–21 Epub Nov 14, 2010.
60. O'Connor AM, Jacobsen MJ: [<http://decisionalaid.ohri.ca>] Decisional conflict: Supporting people experiencing uncertainty about options affecting their health. 2007.
61. Guimond P, Bunn H, O'Connor AM, Jacobsen MJ, Tait VK, Drake ER, Graham ID, Stacey D, Elmslie T: Validation of a tool to assess health practitioners' decision support and communication skills. *Patient Educ Couns* 2003, 50:235–45.
62. O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, Pin˜a IL; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HFACTION randomized controlled trial. *JAMA* 2009;301:1439–1450.
63. Piepoli MF, Conraads V, Corra U, Dickstein K, Francis DP, Jaarsma T, McMurray J, Pieske B, Piotrowicz E, Schmid JP, Anker SD, Solal AC, Filippatos GS, Hoes AW, Gielen S, Giannuzzi P, Ponikowski PP. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. *Eur J Heart Fail* 2011;13:347–357.
64. Mancini DM, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. *Circulation* 1992;85:1364–73.
65. Chati Z, et al. Physical deconditioning may be a mechanism for the skeletal muscle energy phosphate muscle metabolism abnormalities in chronic heart failure. *Am Heart J* 1996;131:560–6.
66. Meyer K, et al. Effects of exercise training and activity restriction in 6-minute walking test performance in patients with chronic heart failure. *Am Heart J* 1997;133:447–53.
67. Sinoway LI. Effect of conditioning and deconditioning stimuli on metabolically determined blood flow in humans and implications for congestive heart failure. *Am J Cardiol* 1998;62(Suppl E):45E–48E.
68. Davies EJ, Moxham T, Rees K, Singh S, Coats AJ, Ebrahim S, Lough F, Taylor RS. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. *Eur J Heart Fail*. 2010;12:706–715.
69. Stewart S, et al. Prolonged beneficial effects of a homebased intervention on unplanned readmissions and mortality among patients with congestive heart failure. *Arch Intern Med* 1999;159:257–61.
70. Fonarow GC, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. *J Am Coll Cardiol* 1997;30:725–35.
71. The National Heart Foundation of New Zealand, the Cardiac Society of Australia and New Zealand (CSANZ), and the Royal New Zealand College of General Practitioners Working Party. New Zealand guidelines for the management of chronic heart failure. *NZ Med J* 1997;110:99–107.
72. The Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. *Eur Heart J* 1997;18:736–53.
73. Evangelista LS, Heber D, Li Z, Bowerman S, Hamilton MA, et al. (2009) Reduced body weight and adiposity with a high-protein diet improves functional status, lipid profiles, glycemic control, and quality of life in patients with heart failure: a feasibility study. *J Cardiovasc Nurs* 24: 207–215.
75. Bohlen JG, Held JP, Sanderson MO, Patterson RP. Heart rate, rate-pressure product, and oxygen uptake during four sexual activities. *Archives of Internal Medicine* 1984;144:1745–8.
76. Cheitlin MD, Hutter AM, Jr., Brindis RG, Ganz P, Kaul S, Russell RO, Jr. et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. *Circulation* 1999; 99:168–77.
77. Masson S, Marchioli R, Mozaffarian D, Bernasconi R. et al. Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: Relation with fish intake, circulating biomarkers, and mortality. *Am Heart J*. 2013 Feb;165(2):208-15.e4

78. Smeulders ES, van Haastregt JC, Janssen-Boyne JJ, Stoffers HE, van Eijk JT, Kempen GI. Feasibility of a group-based self-management program among congestive heart failure patients. *Heart Lung*. 2009 Nov-Dec;38(6):499-512.
79. Koelling TM, Johnson ML, Cody RJ, Aaronson KD. Discharge education improves clinical outcomes in patients with chronic heart failure. *Circulation* 2005, 111:179–185
80. Laramee AS, Levinsky SK, Sargent J, Ross R, Callas P. Case management in a heterogenous congestive heart failure population: A randomized controlled trial. *Arch Intern Med* 2003, 163:809–817
81. Williams A, Manias E, Walker R. Interventions to improve medication adherence in people with multiple chronic conditions: A systematic review. *J Adv Nurs* 2008, 63:132–143
82. Moser DK, Mann DL. Improving outcomes in heart failure: It's not unusual beyond usual care. *Circulation* 2002,
83. Roccaforte R, Demers C, Baldassarre F, Teo KK, Yusuf S. Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis. *Eur J Heart Fail* 2005;7:1133–1144.
84. Grady KL, Dracup K, Kennedy G, Moser DK, Piano M, Stevenson LW et al. Team management of patients with heart failure: A statement for healthcare professionals from the Cardiovascular Nursing Council of the American Heart Association. *Circulation* 2000, 102:2443–2456
85. Jaarsma T, Halfens R, Huijjer Abu-Saad H, Dracup K, Gorgels T, van Ree J et al. Effects of education and support on self-care and resource utilization in patients with heart failure. *Eur Heart J* 1999, 20:673–682
86. Stromberg A, Martensson J, Fridlund B, Levin LA, Karlsson JE, Dahlstrom U. Nurse-led heart failure clinics improve survival and self-care behaviour in patients with heart failure: results from a prospective, randomised trial. *Eur Heart J* 2003;24:1014–1023.
87. Clark RA, Inglis SC, McAlister FA, Cleland JG, Stewart S. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. *BMJ* 2007;334:942.
88. Domingues, Fernanda B., et al. "Education and telephone monitoring by nurses of patients with heart failure: randomized clinical trial." *Arquivos Brasileiros de Cardiologia* 96.3 (2011): 233-239.
89. Clark AM, Savard LA, Thompson DR. What is the strength of evidence for heart failure disease-management programs? *J Am Coll Cardiol* 2009, 54:397–401
90. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. *J Am Coll Cardiol* 2004;44:810–819.
91. Kuehneman T., Saulsbury D., Splett P., Chapman D.B. Demonstrating the impact of nutrition intervention in a heart failure program. *J. Am. Diet. Assoc.* 2002;102:1790-1794.
92. Neily J.B., Toto K.H., Gardner E.B., Rame J.E., Yancy C.W., Sheffield M.A., et al. Potential contributing factors to noncompliance with dietary sodium restriction in patients with heart failure. *Am. Heart J.* 2002;143:29-33.
93. Fujii W, et al. Effects of intracoronary caffeine on left ventricular mechanoenergetics in Ca²⁺ overload failing in rat hearts. *Jpn J Physiol* 1998;48(5):373–81.
94. Wilson JR, Chomsky DB, Dahle K. Exercise in heart failure. In: Moser DK, Riegel B, editors. *Improving outcomes in heart failure*. Gaithersburg7 Aspen Publishers Inc., 2001
95. Edward J. Davies, Tiffany Moxham, Karen Rees, Sally Singh, Andrew J.S. Coats, Shah Ebrahim, Fiona Lough, and Rod S. Taylor. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. *European Journal of Heart Failure* (2010) 12, 706–715
96. Moser DK, Worster PL. Effect of psychosocial factors on physiologic outcomes in patients with heart failure. *J Cardiovasc Nurs* 2000;14:106 – 15.
97. Havranek EP, Ware MG, Lowes BD. Prevalence of depression in congestive heart failure. *Am J Cardiol* 1999;84:348 – 50.
98. Jacob S, Sebastian JC, Abraham G. Depression and congestive heart failure: are antidepressants underutilized? *Eur J Heart Fail* 2003;5:399 – 400.

99. Januzzi JL, Stern TA, Pasternak RC, DeSantis RW. The influence of anxiety and depression on outcomes of patients with coronary artery disease. *Arch Intern Med* 2000;160:1913 – 21.
100. Krumholz HM, Butler J, Miller J, et al. Prognostic importance of emotional support for elderly patients hospitalized with heart failure. *Circulation* 1998;97:958 – 64.
101. Chin MH, Goldman L. Correlates of early hospital readmission or death in patients with congestive heart failure. *Am J Cardiol* 1997;79:1640 – 4.
102. Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. *Arch Intern Med* 2001;161:1849– 56.
103. Berkman LF, et al, Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICH) Randomized Trial. *JAMA* 2003;289(23):3106–16.
104. Gibbs LM, Addington-Hall J, Gibbs SJ. Dying from heart failure: lessons from palliative care. *BMJ* 1998; 317:961–2.
105. Alla F, et al. Self-rating of quality of life provides additional prognostic information in heart failure. Insights into the EPICAL study. *Eur J Heart Fail* 2002;4(3):337–43.
106. Gannon C. Palliative care in terminal cardiac failure. *BMJ* 1995;310:1410–11.
107. Rich M.W., Gray D.B., Beckham V., Wittenberg C., Luther P. Effect of a multidisciplinary intervention on medication compliance in elderly patients with congestive heart failure. *Am. J. Med.* 1996;101:270-276.
108. Rich M.W., Beckham V., Wittenberg C., Leven C.L., Freedland K.E., Carney R.M. A multidisciplinary intervention to prevent readmission of elderly patients with congestive heart failure. *N. Engl. J. Med.* 1995;333:1190-1195.
109. Prevention of heart failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. *Circulation* 2008;117:2544-2565;)
110. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts), (2007). European guidelines on cardiovascular disease prevention in clinical practice. *European Cardiovascular Prevention Rehabilitation*. Vol. 14.
111. American Heart Association Nutrition Committee. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J. Diet and lifestyle recommendations revision 2006: A scientific statement from the American Heart Association Nutrition Committee. *Circulation*.2006;114:82–96
112. Kenchaiah S, Narula J, Vasan RS. Risk factors for heart failure. *Med Clin North Am.* 2004;88:1145–1172.
113. Pittilo M. Cigarette smoking, endothelial injury and cardiovascular disease. *Int J Exp Pathol.* 2000;81:219 – 230.
114. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. *Arch Intern Med.* 2001;161:996 –1002
115. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet* 2003;362:772– 776
116. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. *J Am CollCardiol* 2002;40:1414–1421.
118. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. *Ann Intern Med.* 2002;136:493–503.
119. Vollmer WM, Sacks FM, Ard J, Appel LJ, Bray GA, Simons-Morton DG, Conlin PR, Svetkey LP, Erlinger TP, Moore TJ, Karanja N; DASH Sodium Trial Collaborative Research Group. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. *Ann Intern Med.* 2001;135:1019 –1028.

120. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER III, Simons-Morton DG, Karanja N, Lin PH; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. *N Engl J Med.* 2001;344:3–10.
121. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. *J Am Coll Cardiol.* 1993;22(suppl A):6A–13A.
122. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. *J Am Coll Cardiol.* 2000;35:1628–1637.
123. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, Pinkett T, Ghali JK, Wilson AC. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. *Am J Cardiol.* 1996;77:1017–1020.
124. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ.* 2000;321:405–412.
125. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV. Glycemic control and heart failure among adult patients with diabetes. *Circulation.* 2001;103:2668–2673.
126. The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. *N Engl J Med.* 2010;362:1477–1490
127. MacDonald MR, Eurich DT, Majumdar SR, Lewsey JD, Bhagra S, Jhund PS, Petrie MC, McMurray JJ, Petrie JR, McAlister FA. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case–control study from the U.K. General Practice Research Database. *Diabetes Care* 2010;33:1213–1218.
128. Hummel S, Piercy J, Wright R, Davie A, Bagust A, McMurray J. An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study. Application to the United Kingdom. *Pharmacoeconomics* 1997;12:182–92.
129. McMurray JJ, McGuire A, Davie AP, Hughes D. Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction. *European Heart Journal* 1997;18:1411–5.
130. Schillaci G, Vaudo G, Reboldi G, Verdecchia P, Lupattelli G, Pasqualini L, Porcellati C, Mannarino E. High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. *J Hypertens.* 2001;19:2265–2270.
131. McKeown PP, Logan K, McKinley MC, Young IS, Woodside JV. Session 4: CVD, diabetes and cancer: Evidence for the use of the Mediterranean diet in patients with CHD. *Proc Nutr Soc.* 2010 Feb;69(1):45–60. doi: 10.1017/S0029665109991856. Epub 2009 Dec 15. PMID:20003638 [PubMed - indexed for MEDLINE]
132. Mena MP, Sacanella E, Vazquez-Agell M, Morales M, Fitó M, Escoda R, Serrano-Martínez M, Salas-Salvadó J, Benages N, Casas R, Lamuela-Raventós RM, Masanes F, Ros E, Estruch R. Inhibition of circulating immune cell activation: a molecular antiinflammatory effect of the Mediterranean diet. *Am J Clin Nutr.* 2009 Jan;89(1):248–56. doi: 10.3945/ajcn.2008.26094. Epub 2008 Dec 3.
133. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarsen A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. *N Engl J Med* 2007;357:2248–2261
134. Tavazzi L, Maggioni AP, Marchioni R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebocontrolled trial. *Lancet* 2008;372:1231–1239
135. Anker SD, Clark AL, Winkler R, et al. Statin use and survival in patients with chronic heart failure: results from two observational studies with 5200 patients. *Int J Cardiol.* 2006;112(2):234–242.
136. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. *N Engl J Med* 2003;348:1322–1332.
137. Berg GD, Silverstein S, Thomas E, Korn AM. Cost and Utilization Avoidance With Mail Prompts: A Randomized Controlled Trial. *Am J Manag Care.* 2008 Nov;14(11):748–54.

138. Phrommintikul A, Kuanprasert S, Wongcharoen W, et al. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. *Eur Heart J* 2011;32:1730–5.
139. Christenson B, Pauksen K, Sylvan SP. Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity. *Virology* 2008;5
140. Christenson B., Hedlund J., Lundbergh P., Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. *Eur. Resp. J.* 2004;23:363–368.
141. Pneumococcal Vaccination Recommendations .Public Health England available on GOV.UK website
142. Key Facts about Influenza (Flu) & Flu Vaccine Centers for Disease Control and Prevention 1600 Clifton Rd. Atlanta, GA 30333, USA
143. Diller PM, Smucker DR, David B. Comanagement of patients with congestive heart failure by familyphysicians and cardiologists: frequency, timing, and patient characteristics. *Journal of Family Practice* 1999;48:188–95.
144. Weinberger M, Oddone EZ, Henderson WG. Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. *New England Journal of Medicine* 1996;334:1441–7.
145. McDonald K, Ledwidge M, Cahill J, Kelly J, Quigley P, Maurer B *et al.* Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in a high-risk, elderly heart failure population: the potential contributions of specialist care, clinical stability and optimal angiotensin-converting enzyme inhibitor dose at discharge. *European Journal of Heart Failure* 2001;3:209–15.
146. Doughty RN, Wright SP, Pearl A, Walsh HJ, Muncaster S, Whalley GA *et al.* Randomized, controlled trial of integrated heart failure management: The Auckland Heart Failure Management Study. *European Heart Journal* 2002;23:139–46
147. Gattis WA, Hasselblad V, Whellan DJ, O’Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. *Archives of Internal Medicine* 1999; 159:1939–45.
148. Department of Health, Western Australia. Heart Failure Model of Care. Perth: Health Networks Branch, Department of Health, Western Australia; 2008.